[Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
To prepare CD3/CD19 bispecific monoclonal antibody (BsAb) and study its biological effects. The CD3/CD19 BsAb was prepared by using hybri-hybridoma technique. The presence of BsAb was demonstrated by double-isotype ELISA and cell conjugate assay. We obtained three strains of CD3/CD19 quadromas, including a stable one. 51Cr release assay showed that CD3/CD19 supernatants, CD3/CD19 purified antibody and CD3/CD19 chemical heterocongjugate greatly enhanced the cytotoxic activity of CD3 AK cells against Nalm-6 cells (P < 0.05-0.001). The CD3/CD19 BsAb we prepared was efficient in redirecting activated T cells against target tumor cells. This indicates that the CD3/CD19 BsAb has potential value of clinical use.